BioWorld

Aug. 12, 2009

Cracking the IPO Window: Who's After Cumberland?

Cumberland Pharmaceuticals Inc. may not be a traditional biotech, but it's still the first drug company to price an initial public offering since Bioheart Inc.'s measly $5.8 million debut 15 months ago. (BioWorld Today) Read More

Avanir 'Zenvia' Wall Street with Positive Phase III Results in PBA

Kynapid Stall Narrows Label But Cardiome Forges Ahead

REMS Question Still Lingers After Fresh D-Mab Risk News

Chimerix Gets $16.1M to Push Antiviral with Double Potential

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...